Rebalancing the inflammatory trajectory from inflammatory bowel disease to colitis-associated colorectal cancer via artemisinin-based multitarget therapy

Key Points

• Colitis-associated colorectal cancer incidence may be reduced by targeting inflammatory pathways.
• The study identifies artemisinin-based multitarget therapy as a potential intervention.
• Assessment used a combination of effects on inflammation and cancer progression.
• This approach highlights the need for further exploration of therapeutic options in inflammatory bowel disease.